July 2005

Recurrent miscarriage project update

In response to speculation in a national newspaper, listed biopharmaceutical company GroPep Limited (ASX: GRO) announced today that ethics committee approval has been received to conduct a clinical research study as part of the ongoing development of its Recurrent Miscarriage project (PV903). The ethics approval is subject to a number of conditions.

The study aims to characterise immune cell populations from the cervix of healthy women as a basis for further studies that will investigate the effect of PV903 in a Phase I clinical trial, planned for 2006.

GroPep will continue to keep the market updated as further information becomes available on the status of the PV903 project.

GroPep is a world leader in the development, manufacture and commercialisation of biologically active proteins for cell culture and biomedical research. The Company has an active biopharmaceutical development program that establishes proof of concept for products in humans and partners the later stages of product development and marketing with major pharmaceutical companies. GroPep is listed on the Australian Stock Exchange Limited (ASX code: GRO).

Further Information:
Mr Tony Mitchell
Chief Financial Officer/Investor Relations Ph: 61-883-547-700
[email protected]